Neuroprotection by Mucuna pruriens in Neurodegenerative Diseases

Walia Zahra1, Hareram Birla1, Saumitra Sen Singh1

  • 1Department of Biochemistry, Institute of Science, Banaras Hindu University, Varanasi, 221005, India.

Insights

Mucuna pruriens seeds show promise for treating neurodegenerative diseases like Parkinson's disease (PD), Alzheimer's disease (AD), Amyotrophic lateral sclerosis (ALS), and stroke. Research highlights its neuroprotective potential and identifies therapeutic targets for these conditions.

Area of Science:

  • Pharmacology and Ethnobotany
  • Neuroscience and Neurodegenerative Diseases

Background:

  • Mucuna pruriens (Fabaceae) is a medicinal plant recognized for its antioxidant and anti-inflammatory properties.
  • It holds a significant place in Ayurvedic medicine, traditionally used for neurological disorders and male infertility.
  • The plant's seeds are particularly valued for their potent medicinal properties.

Purpose of the Study:

  • To review the pathogenesis of Parkinson's disease (PD), Alzheimer's disease (AD), Amyotrophic lateral sclerosis (ALS), and stroke.
  • To summarize the medicinal importance of Mucuna pruriens in treating these neurodegenerative conditions.
  • To identify potential therapeutic targets for Mucuna pruriens in neuroprotection.

Main Methods:

  • Literature review focusing on the pathogenesis of PD, AD, ALS, and stroke.
  • Analysis of studies investigating Mucuna pruriens extract in various neurodegenerative disease models.
  • Discussion of the neuroprotective effects and potential mechanisms of action of Mucuna pruriens.

Main Results:

  • Mucuna pruriens extract has demonstrated efficacy in preclinical models of neurodegenerative diseases.
  • The plant's extract shows potential in ameliorating neurodegeneration associated with PD, AD, ALS, and stroke.
  • Key targets for Mucuna pruriens' neuroprotective activity have been identified.

Conclusions:

  • Mucuna pruriens exhibits significant neuroprotective potential against a range of neurodegenerative disorders.
  • Further research into the identified therapeutic targets can validate its use in clinical settings.
  • Mucuna pruriens represents a promising natural therapeutic agent for neurological conditions.

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
767
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
414
Neural Regulation01:37

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
40.4K
The Blood-brain Barrier00:49

The Blood-brain Barrier

Overview
49.4K
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.6K